P3 Health Partners Inc. Form 8-K Summary
Business Context and Reporting Period
P3 Health Partners Inc. filed a Current Report on Form 8-K dated October 18, 2022, reporting developments concerning its Nasdaq listing status. The filing is not a periodic financial report and does not provide operating results for a reporting period.
Financial Metrics and Liquidity
The filing does not provide clear values for revenue, profit, cash flow, margins, debt, liquidity, or other financial metrics.
Material Changes and Listing Status
- On October 18, 2022, Nasdaq’s Hearing Panel granted the Company’s request to extend the automatic 15-day stay of suspension.
- The extension maintained trading of the Company’s Class A common stock and warrants on Nasdaq pending a hearing and final Panel determination.
- Nasdaq had initiated delisting proceedings on September 28, 2022, because the Company was delinquent in filing its Form 10-K for the year ended December 31, 2021, and Forms 10-Q for the quarters ended March 31, 2022, and June 30, 2022.
- The Company appealed the delisting determination on October 5, 2022, and requested an extension of the stay, which otherwise would have expired on October 20, 2022.
Outlook, Risks, and Unusual Items
The principal disclosed risk is potential delisting from Nasdaq due to delinquent periodic filings. Continued trading was only maintained pending the Panel hearing and final determination; the filing does not state the ultimate outcome.
The filing refers to a Panel hearing scheduled for November 3, 2020. Because this date predates the October 2022 filing, the text appears to contain a date inconsistency; the filing does not provide a clear corrected hearing date.
Investor Verification Items
- Verify whether the Company subsequently filed its delinquent Form 10-K and Forms 10-Q.
- Verify the Nasdaq Hearing Panel’s final decision and the Company’s continuing listing status.
- Confirm the hearing date, given the apparent reference to November 3, 2020.
- Review subsequent SEC filings for financial results, liquidity, debt obligations, and any going-concern or financing disclosures.